Research programme: autologous T cell therapies - TxCell

Drug Profile

Research programme: autologous T cell therapies - TxCell

Alternative Names: Ag-Treg therapeutics - TxCell; Balancell; CAR-Treg-TxCell; CellArthrix; Col-Treg-TxCell; HSP60-Treg-TxCell; Myelin-Treg-TxCell; Tr1 cell therapy - TxCell; TX-MSD

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator TxCell
  • Developer Ospedale San Raffaele; TxCell; University of Lubeck
  • Class CAR-T cell therapies; Cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune-mediated uveitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bullous pemphigoid; Immune-mediated uveitis
  • Research Lupus nephritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in France (IV)
  • 01 Jun 2016 TxCell and Lubek Institute of Experimental Dermatology, of the University of Lubeck enter into collaboration to develop CAR-Treg-based cellular immunotherapy for Bullous Pemphigoid
  • 01 Jun 2016 Preclinical trials in Bullous pemphigoid in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top